Biomarker & Diagnostics

Hanson WadeProductsBiomarker & Diagnostics

Bdx

Biomarker & Diagnostics

Reimagine Precision Medicine: Integrating Biomarker & Diagnostic Strategies to Maximize Patient Outcomes

With over 10 years of experience, the Biomarkers & Diagnostics series has been dedicated to serving pioneers in the liquid biopsy, biomarker, diagnostics field, enabling the advancement of precision medicine and maximizing patient outcomes.

As we strive to develop safer, more effective and affordable medicine for targeted patient populations, the ability to discover, translate, validate and adopt novel predictive biomarkers into clinically validated diagnostics will be critical to patient success and in giving drug developers a competitive edge.

Whether you are new to this field or a seasoned expert, we are proud to be the platform serving you with end-to-end biomarker and diagnostic information.

We strive to spark conversations and exchange with your industry peers today, supporting you to define, adopt and implement a robust biomarker and diagnostic strategy to serve patients tomorrow!

Bringing together thought leaders and pioneers in the biomarker, CDx and precision medicine fields, the BDx portfolio provides much needed platforms for candid conversations on how to define, adopt and implement a CDx strategy to ensure your drug candidates are regulatory compliant, achieve reimbursement and gain market share.


“The ability to connect and share information with industry peers is paramount in the field of precision medicine. This transference of information enables health care providers to best serve their patients seeking to receive the knowledge and directly benefit from the applications of precision medicine.  As leaders in the field, it would be a disservice to the patient to not allow for such a meeting of the minds as provided by this event. To be sure, this event empowers us as leaders to face the challenges that tomorrow brings.”
Novartis


“The ability to connect and share information with industry peers is paramount in the field of precision medicine. This transference of information enables health care providers to best serve their patients seeking to receive the knowledge and directly benefit from the applications of precision medicine.  As leaders in the field, it would be a disservice to the patient to not allow for such a meeting of the minds as provided by this event. To be sure, this event empowers us as leaders to face the challenges that tomorrow brings.”
Michael Kiebish, Chief Precision Medicine Officer, BERG


“Great work! It was evident by the professionals who attended and presented, that people are there to make a difference in the CB/CDx world. ”
Senior Sales Executive, Quansys Biosciences